Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Techne Completes Exosome Dx Acquisition

NEW YORK (360Dx) – Bio-Techne said after the close of the market on Wednesday that it has completed its acquisition of Exosome Diagnostics for up to $575 million.

The deal was originally announced in late June. Bio-Techne paid $250 million in cash up front and could pay up to an additional $325 million contingent on the achievement of certain future milestones. The company had previously stated it would finance the deal through a combination of cash on hand and a revolving line of credit facility. 

Bio-Techne is scheduled to release its financial results on Aug. 7 before the market opens.

Exosome, which is based in Waltham, Massachusetts, markets a urine-based test called ExoDx Prostate (IntelliScore) to help clinicians determine whether a patient with an ambiguous PSA test needs a prostate biopsy.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.